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Abstract
Macromolecular nanostructures that are used as drug carriers are character-
ized by their loading and release kinetics. Release studies commonly employ
the dialysis method, in which a cellulose membrane separates the solution of
released drug from the nanocarrier solution. We demonstrate that it is nec-
essary to take the effect of the dialysis membrane on the release kinetics into
account. Using a two-step approach, consisting of a calibration experiment of
drug diffusion through the dialysis membrane in the absence of nanocarriers,
and an experiment in the presence of nanocarriers, we are able to determine all
kinetic rates and in particular to disentangle kinetic dialysis membrane prop-
erties from kinetic nanocarrier properties. We apply our general approach to
experimental dexamethasone release data from core-multishell nanocarriers and
demonstrate that our method yields a consistent description of the nanocarrier
release kinetics.
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1. Introduction
Polymer micelles with fine-tuned core-shell structures gained attention in
recent years for their function as drug delivery systems in tumor therapy and
topical treatment [1, 2, 3, 4, 5]. They enable the transport of hydrophobic drugs
in water by encapsulation in hydrophobic cores while the hydrophilic shells keep
the system dispersed in water and protect the drug from the immune system
[6, 7, 8, 9]. In order to maximize therapeutic efficiency, the release kinetics
of the drug from the nanocarriers has to be optimized and is an important
factor when designing such nanocarriers [10]. Dendritic core-multishell (CMS)
nanocarriers consist of a hyperbranched polar core, an inner shell and an outer
shell. These nanocarriers are able to transport guest molecules in polar as well
as nonpolar solvents and exhibit good tumor targeting as well as efficient topical
drug delivery [11, 12, 13]. A recent study has shown that these CMS carriers
can enhance penetration into the skin [12]. As a transport mechanism this may
allow for drugs to be released into deeper skin layers [14, 15]. In order for the
drug transport via nanocarriers to be efficient, the release time of a specific
drug from the carrier must be similar to the penetration time of the nanocarrier
itself. Thus, reliable determination of drug-nanocarrier release kinetics is of
great importance.
In this work we present a general approach to quantify the release kinetics of
a drug from nano carriers and apply our method to experimental data for dex-
amethasone released from CMS nanocarriers. Drug release from nanocarriers
is in the standard setup studied by drug diffusion through a dialysis mem-
brane, which poses the problem of disentangling the rate of drug release from
the nanocarrier and the rate of drug diffusion through the dialysis membrane
[16, 17, 18, 19]. We solve this problem by a two-step procedure. In the first step,
we perform a calibration experiment testing the release of dexamethasone from
the aqueous solution inside of a dialysis bag to an outside phosphate-buffered
saline solution in the absence of nanocarriers. Here we determine the drug dif-
fusion rate through the dialysis membrane. In the second step, we measure
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the release kinetics from nanocarriers, and use in the analysis of the data the
membrane diffusion rate from the calibration experiment. For the specific dial-
ysis membrane and CMS nanocarrier used in our experiments, we find for the
membrane release rate of dexamethasone rMI = 0.052 min
−1 and for the CMS
nanocarrier release rate of dexamethasone rNI = 0.015 min
−1. We conclude
that in our specific system, the release rate from nanocarriers is only roughly
three times smaller than the membrane release rate and thus both rates are of
the same order. In the following section we will elaborate on the structure of
the CMS nanocarriers as well as on the experimental details and the theoretical
model.
2. Materials and methods
CMS nanocarrier preparation. The CMS nanocarriers we used in our experi-
ments consist of a polar core surrounded by a poly(ε-caprolactone) (PCL) inner
shell and a monomethoxypoly(ethylene glycol) (mPEG) outer shell. The molec-
ular weight of a single nanocarrier is 163.8 kDa. Details about synthesis and
structure of the nanocarriers have been published previously [20].
Dexamethasone loading and release studies. 12 mg of dexamethasone film was
incubated with 6 ml of CMS aqueous solution with a nanocarrier concentration
of cCMS = 15 mg/ml. After 30 s ultrasonication, 3 ml of solution was with-
drawn and filtered immediately with a regenerated cellulose (RC) membrane
filter (0.45 µm pore size). After 3 min of additional ultrasonication, the remain-
ing 3 ml were filtered. At the start of the release experiment, 0.6 ml of each
solution was placed in a dialysis bag with a molecular weight cut-off (MWCO)
of 3.5 kDa. Since dexamethasone has a molecular weight of 392.46 Da [21], the
dialysis membrane holds back the nanocarriers but lets the drug quite easily
pass with a rate that we determine in the calibration experiment. The respec-
tive dialysis bag was then immersed in 30 ml of phosphate-buffered saline (PBS).
Drug release studies were performed in a bioshaker with 100 rpm at 37 ◦C. Since
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the dexamthasone solution is throughly filtered before usage, we can safely as-
sume that it corresponds to an equilibrium saturated solution and neglect the
presence of aggregates in our analysis. Samples of 0.1 ml volume were peri-
odically removed from the outside solution and the same volume of pure PBS
was added. The amount of released dexamethasone was determined by high-
performance liquid chromatography (HPLC). The HPLC measurements were
carried out on a Knauer Smartline-HPLC system, equipped with a reversed-
phase (RP) -C18 column (250 mm × 4 mm, 5µm particle size) and an UV/VIS
detector at λ = 245 nm. The mobile phase was an acetonitril-water (40:60, v/v)
mixture with a flow-rate of 1 ml/min. For comparison, the release of free dex-
amethasone without CMS nanocarriers was conducted in the same condition.
Each experiment was repeated three times. The release data are given by the















First order rate equations. We describe the release of dexamethasone using a
four-state model schematically illustrated in Fig. 1. We denote the fractions of
dexamethasone inside the nanocarriers, the inner solution volume, the dialysis
membrane and the outer solution volume as ΦN,ΦI,ΦM and ΦO, respectively.
The release kinetics of dexamethasone from the CMS nanocarriers can be de-
scribed by a system of coupled rate equations:
dΦN
dt
≡ Φ˙N (t) = −rNIΦN (t) + rINΦI(t), (2)
dΦI
dt
≡ Φ˙I(t) = −(rIN + rIM)ΦI(t) + rNIΦN (t) + rMIΦM (t), (3)
dΦM
dt
≡ Φ˙M (t) = −(rMI + rMO)ΦM (t) + rIMΦI(t) + rOMΦO(t), (4)
dΦO
dt










Figure 1: Schematic illustration of the experimental setup: The dialysis bag is immersed in
the outer solution with a volume VO. The black dots schematically denote dexamethasone
molecules, that are either inside the nanocarriers (N), the inner solution (I) with a volume
VI , the membrane (M) or the outer solution (O). During the experiment dexamethasone first
diffuses from the nanoparticle interior to the inner solution, then into the membrane and
finally into the outer solution. The dialysis membrane is impenetrable for the nanocarriers,
leading to the desired separation of the released dexamethasone from the nanocarriers.
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where rNI is the transition rate of going from state N to state I and analogous
for the other rates. Two properties are used to simplify the set of equations
(2-5). One is the conservation of the total amount of drug,
ΦN (t) + ΦI(t) + ΦM (t) + ΦO(t) = 1. (6)
The other is the rate symmetry
rMI = rMO, (7)
which reflects that the inner and outer membrane surfaces have identical prop-
erties and areas. Note that we neglect any diffusive process inside the solutions,
the nanocarriers and the membrane. This means that we assume the membrane
to be relatively thin and the solutions to be well-mixed. We also neglect the
finite drug loading capacity of the nanocarriers, which would lead to non-linear
effects. This assumption is justified since the nanocarriers are only loaded with
a few dexamethasone molecules at the beginning of the release experiments and
thus should be far from their loading capacity, as we will demonstrate in the Dis-
cussion section at the end. Using eq. (6) and (7), the simplified set of equations
is given by:
Φ˙N (t) = −rNIΦN (t) + rINΦI(t), (8)
Φ˙I(t) = − (rIM + rIN) ΦI(t)+rNIΦN (t)+rMI (1− ΦI(t)− ΦO(t)− ΦN (t)) , (9)
Φ˙O(t) = −rOMΦO(t) + rMI (1− ΦI(t)− ΦO(t)− ΦN (t)) . (10)
In the calibration experiments in the absence of CMS nanocarriers, the above
system reduces to a three-state model (I ↔ M ↔ O) which is fully described
by the two equations:
Φ˙I(t) = −rIMΦI(t) + rMI (1− ΦI(t)− ΦO(t)) , (11)
Φ˙O(t) = −rOMΦO(t) + rMI (1− ΦI(t)− ΦO(t)) . (12)
6
The solution of equations (11-12) for the initial condition Φ0I ≡ ΦI(0) = 1 (an
explicit derivation is found in the supplement) can be given in terms of the







s(s− s1)(s− s2) . (13)




















MI − 2rIMrOM + r2OM
)
. (15)
One can further reduce the number of parameters to two by invoking the relation
VIrIM = VOrOM, (16)
which reflects that the rate for a drug molecule to hit the membrane from
the inside or outside solution is inversely proportional to the solution volume,
denoted by VI and VO. After back transforming eq. (13) we find the time
dependent fraction of dexamethasone outside the dialysis bag, ΦO(t), as
ΦO(t) = rIMrMI
s1 − s2 + s2es1t − s1es2t
s1s2(s1 − s2) , (17)
which depends on only two parameters, rIM and rMI, since VI = 0.6 ml and
VO = 30 ml are known experimental parameters. This function is used as the
model function for fitting the release data from the calibration experiments in
the absence of CMS nanocarriers. The equilibrium fractions follow from the














Since the inner and the outer solution have the same dexamethasone solubility,







Using this assumption we can determine the equilibrium fractions as:
Φ∗I =
rMIVI








rIMVI + rMI(VI + VO)
. (23)
The equilibrium fraction of dexamethasone inside the dialysis membrane, Φ∗M ,
is called the retention fraction, and it plays an important role for the character-
ization of a dialysis membrane.
The solution of the rate equations in the presence of CMS nanocarriers is
more involved. The derivation involves the roots of a third order polynomial,
which we denote as s1, s2 and s3 and which depend on the transition rates.
A full derivation can be found in the supplement. Using that in the begin-
ning of the release experiment, the dexamethasone is inside the inner solution
(Φ0N ≡ ΦN (0),Φ0I ≡ ΦI(0),Φ0N + Φ0I = 1), the time dependent dexamethasone







































which is in line with the fact that the experimental release data do not differ
significantly for the two different loading times, 30 s and 3 min (see Fig. 3a).
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From the maximal dexamethasone solubility in water, cmaxDMS = 0.075 mg/ml,
measured at room temperature, and the maximal total dexamethasone concen-
tration in aqueous solution including CMS of a concentration cCMS = 15 mg/ml,







DMS = 0.43, (26)
and consequently the initial fraction in the nanocarriers, Φ0N , as
Φ0N = 1− Φ0I = 0.57. (27)
Using the rates rIM and rMI that we determined from the calibration experiment,
our fit function has only one remaining unknown parameter which we choose
to be the rate at which dexamethasone is released from the nanocarriers to the
aqueous solution volume VI inside the dialysis bag, rNI .
We summarize all assumptions made in our theoretical description of the
experimental release kinetics:
1. In order for the description in terms of rate equations to be valid, the drug
concentration in each compartment has to be homogeneous. This means
that we neglect diffusion effects inside the solutions, in the nanocarriers
and in the dialysis membrane.
2. The total amount of drug in the system does not change throughout the
release experiment.
3. The loading of nanocarriers in solution prior to the release experiment
corresponds to thermodynamic equilibrium.
4. The membrane is thin, so that the rates rMI and rMO are equal.
5. The loading of the nanocarriers is far from their loading capacity so that
linear kinetics is valid.
3. Results
Dexamethasone release kinetics through dialysis membrane: calibration experi-
ment. We fit the average release data of the three runs of the calibration exper-
9






















































Figure 2: a) Released fraction of dexamethasone outside the dialysis bag ΦO(t) from the cali-
bration experiment (points) in absence of CMS nanocarriers and the best estimated fit accord-
ing to eq. (17) (dashed line). The fit parameters are 1/rIM = 3 min and 1/rMI = 19 min. b)
Different curves for fixed 1/rMI = 19 min and 1/rIM = 1, 3, 10, 20, 30 min (violet, blue, green,
yellow, red). c) Different curves for fixed 1/rIM = 3 min and 1/rMI = 5, 10, 19, 30, 40 min
(violet, blue, green, yellow, red).
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iment in absence of CMS nanocarriers, denoted as ΦO, to eq. (17) using the in-
ternal function NonlinearModelFit of Mathematica (Version 10.4.0.0) [22]. The
squared reciprocals of the experimental errors, calculated according to eq. (1),
are used as weights for the model fit. Fig. 2a displays the release data measured
in the calibration experiment in the absence of CMS nanocarriers as well as a
plot of the fit function in eq. (17). We find that the release rate for dexam-
ethasone from the inner solution volume of the dialysis bag into the membrane
is rIM = 0.342 min
−1 (1/rIM = 3 min) with an estimated standard error of
∆rIM = 0.053 min
−1. The rate for dexamethasone going back from the dialysis
membrane into the inner solution volume is rMI = 0.052 min
−1 (1/rMI = 19 min)
with an estimated standard error of ∆rMI = 0.005 min
−1. The remaining rates
are calculated according to eq. (7) as rMO = rMI = 0.052 min
−1 and eq. (16) as
rOM = rIMVI/VO = 0.007 min
−1 (1/rOM = 146 min). The resulting equilibrium





0.868 and the membrane retention is Φ∗M = 1− Φ∗I − Φ∗O = 0.115. This means
that roughly 10 % of dexamethasone is in equilibrium retained in the mem-
brane, which is a significant fraction. The agreement between the data and
the fit function in Fig. 2a is not perfect, which might point to the relevance
of diffusion effects inside the dialysis membrane. Fig. 2b and 2c display curves
where one of the two parameters is fixed to the best fit parameter value and the
other is varied over a range of more than one order of magnitude. The curves
demonstrate that the fitting procedure is quite robust.
Dexamethasone release kinetics from CMS nanocarriers. We next use the re-
sults of the fit of the calibration experiment in the absence of CMS nanocarriers
for rIM and rMI to fit the time dependent fraction of dexamethasone ΦO(t) in
the presence of CMS nanocarriers inside the dialysis bag. We find the dexam-
ethasone transition rate from the nanocarriers to the aqueous solution volume
VI , to be rNI = 0.015 min
−1 (1/rNI = 66 min) with an estimated standard error
of ∆rNI = 0.003 min
−1. Fig. 3a displays the experimental release data for two































































Figure 3: a) Released fraction of dexamethasone outside the dialysis bag ΦO(t) from the
release experiment in the absence of nanocarriers (blue points) and including nanocarriers
(yellow points for 30 s loading time, green points for 3 min loading time) and the best estimated
fits (dashed lines). The green curve corresponds to a dexamethasone release rate from the
nanocarriers of rNI = 0.015 min
−1 (τNI = 66 min). The other two parameters, fixed by the
calibration experiment, are τIM = 3 min and τMI = 19 min. b) Curves for different values
of τNI = 0, 10,20, 40, 66, 100, 150 min (violet, blue, light blue, green, yellow, orange, red),
τIM = 3 min and τMI = 19 min. c) Curves for fixed τNI = 66 min and various values of rMI and
rIM at a constant ratio, namely τIM/τMI = 0/0, 0.03/0.19, 3/19, 7/48, 15/97, 29/194 min/min
(red, yellow, green, light blue, blue, violet). We see that for τMI > τNI the release kinetics
slows down. If on the other hand the membrane release rate rMI becomes larger than the
nanocarrier release rate rNI, the release kinetics approaches a limiting functional form.
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measured in the calibration experiment in the absence of CMS nanocarriers
(blue symbols) together with the corresponding fit functions. Fig. 3b displays
curves for different transition rates rNI ranging from 150
−1 min−1 up to the limit
of 1/rNI → 0 min. We again conclude that the fit is quite robust. In Fig. 3c,
we compare the experimental data with theoretical release curves for which the
membrane rates rMI and rIM are modified while keeping their ratio fixed. The
curves demonstrate pronounced deviations from the experimental data when
the membrane release rate rMI is significantly smaller than the nanocarrier re-
lease rate rNI. In this case the drug release kinetics becomes dominated by the
membrane transfer kinetics. In the opposite limit, when the membrane rate
rMI is larger than rNI, the curves approach a limiting functional form and the
drug release kinetics is dominated by the release from the nano carriers. We
see from this plot that for the experimental system studied by us, the kinetics
of nanocarrier release and membrane transfer occur on similar time scales and
thus are coupled. Clearly, for the robust analysis of dialysis release experiments
it is favorable to choose a membrane that has faster release kinetics than the
nanocarriers.
4. Discussion
By comparing experimental drug release data in the absence of nanocarriers
with release data including nanocarriers, we can unambiguously estimate the
release rate of dexamethasone from nanocarriers to be approximately rNI =
0.015 min−1, which corresponds to a release time of 1/rNI = 66 min. If we
compare the release time from nanocarriers with the membrane release time
1/rMO = 19 min, we find that they have the same order of magnitude. This
means that the effect of the membrane can not be neglected when modeling the
drug release kinetics from CMS nanocarriers in a typical dialysis experiment. It
transpires that one has to obtain all relevant kinetic parameters in a calibration
experiment in the absence of CMS nanoparticles in order to be able to fit the
more complex release of dexamethasone including nanocarriers.
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We now compare our theoretical analysis of the dexamethasone release data
with a much simpler kinetic model. In Fig. 4 we show the result of a fit using
a single exponential decay given by
ΦO(t) = 1− e−rNIt. (28)
Eq. (28) can be deduced from our general model eq. (24) by taking the limits
rMO → ∞ and rIM → ∞, corresponding to infinitely fast membrane kinetics,
and using an initial condition Φ0N = 1, meaning that initially dexamethasone is
entirely inside the nanocarriers. Fitting the experimental release data using this
simplified model, we obtain a nanocarrier release rate of rNI = 0.0083 min
−1
with an estimated standard error of ∆rNI = 0.0012 min
−1. This corresponds
to a release time of 1/rNI = 121 min, which is roughly two times larger than
the nanocarrier release time obtained from our more realistic four-state model,
which is 1/rNI = 66 min. We conclude, that neglecting the effect of the mem-
brane introduces a significant error in the resulting nanocarrier release rate. In
Fig. 4 we also see that the single-exponential fit does not describe the experi-
mental accurately over the entire time range, which we explain by the fact that
the experimental data exhibit multi-exponential decay.
A subtle point of release kinetics study is the fact that typical models assume
rapid mixing of the solution. In our release study we use a bioshaker in order to
meet this condition. It is important to note that diffusion of the drug without
shaking is not sufficiently fast to provide rapid mixing. For the sake of argument
we calculate the typical diffusion time of a dexamethasone molecule within a
spherical dialysis bag with a volume of 0.6 ml. The radius of the dialysis bag
follows from 0.6 · 10−6 m3 = 43pir3 as r = 5.23 mm. Using Stokes’ law and
the Einstein relation, we find the diffusivity of a dexamethasone molecule as
DDMS = kBT/ (6piηrDMS) = (kB 310.15 K) /
(
6pi 0.69 · 10−3 Pa s · 0.7 nm) =
0.48 nm2/ns, estimating the dexamethasone radius along the long axis as rDMS =
0.7 nm. Consequently the mean time for a dexamethasone molecule to travel a
distance of 5.23 mm is given by τ = r2/ (6DDMS) = 160 min. Interestingly, this

























Figure 4: A single-exponential decay according to eq. (28) is compared with the ex-
perimental release data including nanocarriers. The obtained nanocarrier release rate is
rNI = 0.0083 min
−1, which is only half as large as the rate obtained from the full four-
state model rNI = 0.015 min
−1. In addition to the best fit corresponding to 1/rNI = 121 min
(green), we show curves for the different values 1/rNI = 30, 66, 200, 300 min (violet, light blue,
yellow, red).
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CMS nanocarriers 1/rNI, showing that indeed mixing of the inside of the dial-
ysis bag is important in order to be able to model the experiment by a simple
four-state model.
In order to obtain the nanocarrier loading rate per nanocarrier r˜IN we divide rIN
by the nanocarrier molar concentration in the inner solution volume. The mo-
lar concentration of CMS nanocarriers nCMS follows as nCMS = cCMS/MCMS =











This rescaled loading rate does not depend on the concentration of CMS nanocar-
riers.
Finally, we estimate the chemical potential of a dexamethasone molecule inside
a CMS nanocarrier. Assuming that the CMS nanocarriers have the same density
as water we estimate the total nanocarrier volume as VN = (cCMS · 0.6 ml) /cH2O =
(15 mg/ml · 0.6 ml) / (1000 mg/ml) = 9 µl. We calculate the number of CMS
nanocarriers in 0.6 ml solution with a nanocarrier concentration of cCMS =
15 mg/ml as NCMS = (cCMS · 0.6 ml) / (163.8 kg/mol/NA) = 3.31 · 1016, NA
being the Avogadro constant. By dividing VN by the number of nanocarriers in
the system, we deduce the volume of a single nanocarrier as
V˜N = VN/NCMS =
9 µl
3.31 · 1016 = 272.0 nm
3, (30)
corresponding to a radius rCMS = 4 nm. We can calculate the number of dex-
amethasone molecules in 0.6 ml of solution from the experimental concentration




cCMSDMS · 0.6 ml
)
/ (392.46 g/mol/NA) = 1.59 ·
1017. Using the fact that the concentration outside the nanocarriers corresponds
to the maximal solubility cmaxDMS, we can define the dexamethasone concentration
inside the nanocarriers cNDMS via c
CMS
DMS ·0.6 ml = cNDMS ·VN +cmaxDMS ·(0.6 ml−VN ),
which leads to
cNDMS = 6.61 mg/ml. (31)
16
The number of dexamethasone molecules per nanocarrier is obtained by multi-
plying the concentration cNDMS by the volume of a single nanocarrier, N˜
N
DMS =
cNDMS · V˜N/ (392.46 g/mol/NA) = 2.76. We conclude that the number of dexam-
ethasone molecules per nanocarrier is quite small, validating our linear theoret-
ical description of the experimental data.
The equilibrium loading constant is obtained by dividing the dexametha-
sone concentration inside a nanocarrier by the concentration of dexamethasone
in aqueous solution, K = cNDMS/c
max
DMS = (6.61 mg/ml) / (0.075 mg/ml) = 88.
From the equilibrium constant, we deduce the chemical potential of dexametha-
sone in a nanocarrier as
K = e−µ/(kBT ) =⇒ µ = −4.48 kBT. (32)
We see that dexamethasone strongly prefers the interior of a nanocarrier com-
pared to the aqueous solution, which demonstrates that nanocarriers are highly
efficient for storing and transporting hydrophobic drugs in an aqueous environ-
ment. It is interesting to compare the dexamethasone chemical potential inside
a nanocarrier with the dexamethasone octanol-water partition coefficient, which
is given by logP = 1.83 [23]. Since log(K) = 1.94 is fairly close to the dexam-
ethasone logP value, we conclude that CMS nanocarriers provide a lipophilic
nano-environment that is quite similar to octanol.
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